Legal & General Group Plc Makes New $1.26 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Legal & General Group Plc acquired a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 75,451 shares of the company's stock, valued at approximately $1,263,000. Legal & General Group Plc owned approximately 0.06% of Centessa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares during the last quarter. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at about $777,000. Geode Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 68.7% during the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after acquiring an additional 23,058 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company's stock worth $1,928,000 after purchasing an additional 14,494 shares in the last quarter. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Trading Down 0.2 %

Shares of CNTA stock traded down $0.03 on Tuesday, hitting $13.72. 483,400 shares of the company's stock traded hands, compared to its average volume of 607,394. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -8.97 and a beta of 1.53. The company's fifty day simple moving average is $14.38 and its 200 day simple moving average is $15.86. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. Equities analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reissued an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Finally, Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Buy" and an average target price of $27.71.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 6,471 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the completion of the sale, the insider now directly owns 54,322 shares in the company, valued at $915,868.92. This represents a 10.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the sale, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,476,457.86. This trade represents a 1.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 219,513 shares of company stock worth $3,576,685 in the last ninety days. 11.59% of the stock is owned by insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.